NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $45.25 +0.29 (+0.65%) As of 09:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBC alerts:Sign Up Key Stats Today's Range$45.04▼$45.2550-Day Range$38.66▼$47.7552-Week Range$16.85▼$48.18Volume1,193 shsAverage Volume22,324 shsMarket Capitalization$38.46 millionAssets Under Management$47.26 millionDividend Yield1.44%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF Overview The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus. Read More Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.57%0.51%0.53%Other Expenses0.00%0.47%0.55%0.58%0.55%Total Expense0.79%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.61%Net Expense0.79%0.59%0.63%0.58%0.60% Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBC ETF News HeadlinesThe Zacks Analyst Blog Highlights BWET, GOEX, SLVP, LIT and BBCSeptember 10, 2025 | uk.finance.yahoo.comBBC Virtus LifeSci Biotech Clinical Trials ETFMay 23, 2025 | seekingalpha.comYour free book expiresVeteran trader Bill Poulos is giving away his 'Safe Trade' Options Formula book at no charge - a 5-part framework designed to improve your odds on every options trade you make. The book outlines a repeatable process that works regardless of market conditions. Poulos says the free offer won't last, so the window to claim a copy is limited.May 14 at 1:00 AM | Profits Run (Ad)FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | benzinga.comTech ETFs on the Rise After Four Weeks in Deep RedAugust 19, 2024 | theglobeandmail.comVirtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukSee More Headlines BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $38.56 on January 1st, 2026. Since then, BBC shares have increased by 17.3% and is now trading at $45.25. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and GE Aerospace (GE). Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings125 Fund Statistics Assets Under Management$47.26 million Average Daily Volume$24.69 thousand Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers, LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume5 Put Options4 Call Options1 Short Interest86,200 shs Miscellaneous Outstanding Shares850,000Beta0.91 Creation Unit50,000 Creation Fee$500.00 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report Top 10 BBC HoldingsErasca (NASDAQ:ERAS)Holding Weight: 2.19%Enliven Therapeutics (NASDAQ:ELVN)Holding Weight: 1.81%Tango Therapeutics (NASDAQ:TNGX)Holding Weight: 1.71%Oruka Therapeutics (NASDAQ:ORKA)Holding Weight: 1.67%Spyre Therapeutics (NASDAQ:SYRE)Holding Weight: 1.64%Alumis (NASDAQ:ALMS)Holding Weight: 1.59%Dianthus Therapeutics (NASDAQ:DNTH)Holding Weight: 1.54%Kodiak Sciences (NASDAQ:KOD)Holding Weight: 1.35%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.35%Corvus Pharmaceuticals (NASDAQ:CRVS)Holding Weight: 1.34%Full Holdings DetailsBBC Sector ExposureBBC Industry Exposure This page (NYSEARCA:BBC) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersThe US sanctioned itself out of world reserve status…Russia and Iran are both bypassing the US petrodollar - settling oil trades in alternative currencies while ce...Golden Portfolio | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
